What we do
Incanthera is a revenue-generating, UK-based, oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer.
We are developing a pipeline of tumour-targeting drug delivery systems. The platform
technology enables precise delivery of both new and existing highly potent drugs directly to
tumours. This precision improves tumour selectivity and decreasing the side effects
associated with traditional anti-cancer treatments.
The pipeline utilises well-established & proven treatments, which are known to act on tumours. Therefore, in the company’s opinion the portfolio has been significantly de risked at this stage.
The Company was spun-out in 2010 from the Institute of Cancer Therapeutics (ICT), University of Bradford. To date the University of Bradford has made three assignments of IP which combined with acquisitions have continued to both broaden & strengthen the pipeline.